莫西沙星左氧氟沙星序贯给药对老年重症慢性阻塞性肺疾病急性加重期患者呼吸功能微炎症的影响研究

doi:10.3969/j.issn.1006-6233.2023.04.032

Abstract
Figure/Table
References
Related Citation (12)

Download: PDF (1246 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the effects of sequential administration of moxifloxacin and levofloxacin on respiratory function and microinflammation in elderly patients with severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: 150 elderly patients with severe AECOPD treated in our hospital from March 2019 to March 2022 were selected and divided into group A, B and C by simple random sampling method, with 50 cases in each group. Group A was given moxifloxacin, group B was given levofloxacin, and group C was given moxifloxacin and levofloxacin administered sequentially. The respiratory function indicators [forced expiratory volume in the first second as a percentage of the predicted value (fev1%pred) and forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC)] were compared among the three groups after 1 week of treatment, and the changes of serum microinflammation [intercellular cell adhesion molecule (ICAM)-1, interferon gamma-inducible protein-10 (IP-10)] and immune function [plasma-soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), peripheral blood CD4⁺/CD8⁺] were compared and analyzed before and after treatment. The differences in occurrence of adverse drug reactions among the three groups were compared. Results: After 1 week of treatment, fev1%pred, FEV1/FVC and peripheral blood CD4⁺/CD8⁺ were increased while serum ICAM-1, IP-10 and plasma sTREM-1 were decreased in the three groups the difference was statistically significant (P<0.05). Compared at the soone time the fev1%pred, FEV1/FVC and peripheral blood CD4⁺/CD8⁺ in group A were higher while serum ICAM-1, IP-10 and plasma sTREM-1 were lower than those in group B, and fev1%pred, FEV1/FVC and peripheral blood CD4⁺/CD8⁺ were higher while serum ICAM-1, IP-10 and plasma sTREM-1 were lower in group C compared to groups A and B the difference was statistically significant (P<0.05). The incidence rate of phlebitis in group C was lower than that in groups A and B the difference was statistically significant (P<0.05). There were no statistical differences in the incidence rates of other adverse reactions (P>0.05). Conclusion: Sequential administration of moxifloxacin and levofloxacin can alleviate the microinflammatory response in patients with AECOPD, improve the pulmonary function and immune indicators, and effectively prevent the occurrence of phlebitis.

Key words： Moxifloxacin Levofloxacin Sequential administration Elderly severe acute exacerbation of chronic obstructive pulmonary disease Respiratory function Microinflammation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.04.032 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I4/685